LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Randox Showcases Pioneering Diagnostic Technologies at 2021 AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Image: Randox Showcases Pioneering Diagnostic Technologies at 2021 AACC Clinical Lab Expo (Photo courtesy of Randox Laboratories)
Image: Randox Showcases Pioneering Diagnostic Technologies at 2021 AACC Clinical Lab Expo (Photo courtesy of Randox Laboratories)

Randox Laboratories (Crumlin, UK) showcased its pioneering diagnostic technologies at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, which saw breakthrough innovations shaping the future of clinical testing and patient care.

With more than 400 companies exhibiting, the 2021 AACC Clinical Lab Expo is the premier global laboratory medicine exposition. Among its diverse product range displayed at AACC 2021 were third party quality control solutions, diagnostic reagents which included many niche & superior performance assays, clinical chemistry analyzers, molecular diagnostic solutions for infectious diseases including COVID-19 and patented biochip technology. The revolutionary biochip is capable of simultaneously detecting hundreds of targets from a single patient sample. Complete patient profiling in this way facilitates faster patient testing, earlier diagnosis and improved patient pathways.

Randox also demonstrated its Qnostics range of molecular controls for infectious diseases comprising hundreds of characterized viral, bacterial and fungal targets covering a wide range of diseases and infections. Comprising hundreds of characterized viral, bacterial and fungal targets, the Qnostics range includes transplant associated diseases, respiratory diseases, blood borne viruses, sexually transmitted infections, gastrointestinal infections and central nervous system diseases. The products can be used in the daily monitoring of assay performance, linearity assessment, assay evaluation, validation and verification of new assays and staff training.

Also on display at the event were the company’s Acusera Anti-SARS-CoV-2 controls which support assay validation and routine performance monitoring of serological assays for COVID-19. Conveniently supplied in a liquid format, this control has unrivalled 30-day open vial stability, therefore keeping waste to a minimum.

Related Links:
Randox Laboratories

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more